Clinical Trial Update: Acetazolamide for Treatment Resistant Schizophrenia [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 clinical trial is evaluating acetazolamide for treatment-resistant schizophrenia, with recruitment currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• ACETAZOLAMIDE (acetazolamide)

Snippet

Sponsor: Vishwajit Nimgaonkar, MD PhD | Conditions: Schizophrenia, Schizo Affective Disorder | Phase 1, Phase 2 | Status: RECRUITING